Shield secures Activated Factor XII (AFT) deal
This article was originally published in Clinica
Shield Diagnostics has strengthened its links with Abbott with the signing of a long-awaited licensing agreement for the UK company's Activated Factor XII heart attack prediction test. Under the worldwide agreement, Shield will develop, manufacture and distribute its assay for use on Abbott's IMx automated instrument. While the terms of the deal are confidential, it is understood there are no upfront payments. Mr Evans said the company is looking for additional partners for a deal on AFT, but he stressed that "those that come later pay a higher price".
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.